Research News and Research

RSS

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Total kidney removal not beneficial for elderly patients with confined kidney tumors

A new study indicates that patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed. The research reveals that these patients typically have other medical problems of greater significance and that many should receive more conservative cancer-related care, such as observation or treatments that spare the noncancerous parts of their kidneys. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

10 May 2010

Mice express pain through facial expressions, says study

A new study by researchers from McGill University and the University of British Columbia shows that mice, like humans, express pain through facial expressions.

10 May 2010

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.

10 May 2010

Astute Medical completes $26.5 million series B financing

Astute Medical, Inc., a developer of novel, biomarker-based medical diagnostics, today announced completion of a $26.5 million series B financing co-led by Domain Associates and Delphi Ventures. Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercializing high potential diagnostic products.

10 May 2010

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.

10 May 2010

FASEB scientists call for increased funding for federal science agencies

Scientists from across the country came to Washington on May 5th to advocate for increased funding for federal science agencies as part of the Federation of American Societies for Experimental Biology's (FASEB) annual Capitol Hill Day.

10 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

Repros Therapeutics net loss decreases to $1.1M for first-quarter 2010

Repros Therapeutics today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

Research News and Research

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Bovie Medical first-quarter revenues decrease to $5.6M

Immunomedics third-quarter revenues increase to $10.7 million

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Total kidney removal not beneficial for elderly patients with confined kidney tumors

Mice express pain through facial expressions, says study

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Astute Medical completes $26.5 million series B financing

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Achillion reports lower net loss of $5.6M for first-quarter 2010

FASEB scientists call for increased funding for federal science agencies

Medical options to help prostate cancer patients make informed treatment decisions

Lexicon Pharmaceuticals first-quarter revenues down 61%

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

Repros Therapeutics net loss decreases to $1.1M for first-quarter 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News